Europe Heparin Market Size and Share
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 2.56 Billion |
| Market Size (2030) | USD 3.52 Billion |
| CAGR (2025 - 2030) | 6.60% |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Heparin Market Analysis by Mordor Intelligence
The Europe Heparin Market size is estimated at USD 2.56 billion in 2025, and is expected to reach USD 3.52 billion by 2030, at a CAGR of 6.6% during the forecast period (2025-2030).
Factors such as the rising prevalence of chronic diseases and the increasing geriatric population in Europe are expected to boost market growth. The rising prevalence of chronic disorders around European countries, such as coronary artery disease, heart attacks, and cancer, is a major factor driving the market growth as it is expected to boost the usage of heparin for the management of the disease. For instance, according to the data updated by the European Union in September 2022, cardiovascular diseases are one of the leading causes of morbidity in the European Union. Cardiovascular diseases cover a broad group of medical problems that affect the circulatory system (the heart and blood vessels), often resulting from atherosclerosis, the abnormal build-up of plaque that is made of, among constituents, cholesterol or fatty substances that are deposited on the inside walls of a person’s arteries.
Some of the most common diseases that affect the circulatory system include ischaemic heart disease (heart attacks) and cerebrovascular diseases (strokes). Hence, the high prevalence of such heart disorders in European countries is expected to drive the adoption of heparin, which would drive the growth of the market.
According to the data updated by the Santé Publique France in July 2023, over 433,000 new cancer diagnoses were recorded in 2023 in France, nearly doubling the 216,000 cases found in 1990. The source also stated that new cancer cases in women were increasing faster, with the median age of diagnosis being 68 years old (compared to 70 years old for men). Thus, the increasing prevalence of cancer in France is also expected to boost the demand for heparin, which is often used for the treatment of symptoms such as venous thromboembolism in cancer patients.
In addition, the increasing geriatric population in the region is also expected to enhance market growth as heparin is often used for the management of chronic diseases in older patients. For instance, according to the data updated by the UN World Population Fund Dashboard in 2023, around 23% of the total population in Germany was 65 years or older in 2023. Thus, the high geriatric population in these countries is also expected to increase the usage of heparin.
Therefore, owing to the aforementioned factors, such as the rising prevalence of chronic disorders and the growing geriatric population, the market is anticipated to grow over the forecast period. However, the side effects of heparin and the emergence of oral coagulants are likely to impede market growth.
Europe Heparin Market Trends and Insights
The Low Molecular Weight Heparin (LMWH) Segment is Expected to Witness Significant Growth Over the Forecast Period
Low-molecular-weight heparin (LMWH) is a class of heparin medications that are used in the prevention of blood clots and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction, among others. Factors such as the advantages over the other types of heparin, the high prevalence of cardiovascular disorders such as deep vein thrombosis, myocardial infarction, and coronary artery disease, and the growing geriatric population in European countries are expected to boost the market’s growth.
The increasing burden of cardiovascular disorders is a major factor driving the growth of the segment. For instance, according to an article published by Springer Nature in 2023, an estimated one to two individuals per 1,000 people in Europe are affected with venous thromboembolism every year. Thus, the high prevalence of such cardiovascular diseases in Europe is expected to boost segmental growth, as LMWH is widely used for the treatment of deep vein thrombosis.
Moreover, the advantages associated with LMHW, such as better bioavailability and longer half-life, simplified dosing, and predictable anticoagulant response, are also increasing its adoption for treatment, which is expected to boost the segment’s growth.
Furthermore, according to an article published by the Journal of Expert Review of Pharmacoeconomics & Outcomes Research in April 2022, there was a high prevalence of ischemic heart disease (IHD) in Spain, and it contributed to a significant social and economic burden in the country. Thus, the high prevalence of ischemic heart disease is also expected to boost segmental growth.
As per the data updated by the European Commission in August 2022, more than one-fifth (21.1 %) of the European population was aged 65 and over in 2022. The source also stated that the median age of the European population is increasing; it was 44.4 years in January 2022, meaning that half of the population was older than 44.4 years. Such an anticipated increase in the elderly population growth rate is also associated with the increasing number of chronic diseases, which will boost the usage of heparin for treatment.
Hence, the aforementioned factors, such as the rising prevalence of cardiovascular diseases and the rising geriatric population, are expected to boost the segment’s growth during the forecast period.
The United Kingdom is Expected to Hold a Significant Share of the Market
The United Kingdom is expected to hold a significant share of the market owing to factors such as the easy availability of the latest products and the increase in the adoption of heparin for the management of various chronic diseases. Moreover, the rising prevalence of cardiovascular diseases and cancer and the increasing geriatric population in the country are among the key factors that contribute to the growth of the market in the United Kingdom.
For instance, according to the data published by the British Heart Foundation (BHF) in 2023, there were an estimated 1.14 million inpatient admissions related to heart and circulatory diseases in the United Kingdom in 2022. Thus, with the increasing burden of such cardiovascular diseases across the country, the market is expected to witness strong growth.
The increase in cancer cases across the United Kingdom is one of the major factors expected to fuel the market’s growth over the forecast period. For instance, according to the October 2022 report of Macmillan Cancer Support, the incidence of cancer in the United Kingdom is increasing rapidly. The number of people living with cancer in the United Kingdom is projected to increase from 3.5 million in 2025 to 4 million by 2030.
The increasing geriatric population is likely to increase the market growth over the forecast period, as heparin is often used for the management of chronic diseases in older adults. For instance, according to the 2022 statistics published by the UN Population Fund, in the United Kingdom, about 63% of the population was aged 15-64 years in 2022. In addition, as per the same source, 19% of the population was aged 65 years and above in the same year.
Therefore, owing to the aforementioned factors, such as the high prevalence of various chronic diseases and the increasing geriatric population, the market is anticipated to grow in the United Kingdom.
Competitive Landscape
The European heparin market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known. Some of the key market players include Pfizer Inc., Fresenius Kabi AG, Viatris Inc., B Braun SE, and Baxter International Inc.
Europe Heparin Industry Leaders
-
B Braun SE
-
Baxter International Inc.
-
Pfizer Inc.
-
Fresenius Kabi AG
-
Viatris Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2024: Laboratorios Farmacéuticos ROVI SA, a biopharmaceutical company engaged in research, completed the work on its new plant in Granada, Spain, with the expansion of the existing facilities by 1,620 square meters and the inclusion of a new sodium heparin production line. This new line, authorized to commence commercial activity, is expected to produce up to 88 million syringes of sodium heparin, necessary to obtain low-molecular-weight heparins (LMWHs).
- October 2023: Miratorg and a Russian subsidiary of the Van Hessen Group launched the Geparinus factory in the Kursk region of Russia. The factory is expected to produce the initial form of pharmaceutical heparin.
Europe Heparin Market Report Scope
Heparin is an anticoagulant that is used to decrease the clotting ability of blood and help prevent harmful clots from forming in blood vessels.
The European heparin market is segmented by product, source, application, and geography. By product, the market is segmented into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). By source, the market is segmented into bovine and porcine. By application, the market is segmented into deep vein thrombosis (DVT), atrial fibrillation and heart attack, coronary artery disease, and other applications. By geography, the market is segmented into Germany, the United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (USD) for all the above segments.
| Unfractionated Heparin |
| Low Molecular Weight Heparin (LMWH) |
| Ultra-low Molecular Weight Heparin (ULMWH) |
| Bovine |
| Porcine |
| Deep Vein Thrombosis (DVT) |
| Atrial Fibrillation and Heart Attack |
| Coronery Artery Disease |
| Other Applications |
| Germany |
| United Kingdom |
| France |
| Italy |
| Spain |
| Rest of Europe |
| By Product | Unfractionated Heparin |
| Low Molecular Weight Heparin (LMWH) | |
| Ultra-low Molecular Weight Heparin (ULMWH) | |
| By Source | Bovine |
| Porcine | |
| By Application | Deep Vein Thrombosis (DVT) |
| Atrial Fibrillation and Heart Attack | |
| Coronery Artery Disease | |
| Other Applications | |
| By Geography | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe |
Key Questions Answered in the Report
How big is the Europe Heparin Market?
The Europe Heparin Market size is expected to reach USD 2.56 billion in 2025 and grow at a CAGR of 6.60% to reach USD 3.52 billion by 2030.
What is the current Europe Heparin Market size?
In 2025, the Europe Heparin Market size is expected to reach USD 2.56 billion.
Who are the key players in Europe Heparin Market?
B Braun SE, Baxter International Inc., Pfizer Inc., Fresenius Kabi AG and Viatris Inc. are the major companies operating in the Europe Heparin Market.
What years does this Europe Heparin Market cover, and what was the market size in 2024?
In 2024, the Europe Heparin Market size was estimated at USD 2.39 billion. The report covers the Europe Heparin Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Heparin Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Europe Heparin Market Report
Statistics for the 2025 Europe Heparin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Heparin analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
